BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 24, 2015
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg8/21 cls
Avalanche Biotechnologies Inc. (NASDAQ:AAVL)Chardan CapitalGbola AmusaUpgradeBuy (from neutral)6%$10.62
Amusa upgraded, saying the stock has "oversold below rational levels based on cash/share, technology value, and also M&A considerations." On Aug. 14, the stock dropped 28% after the company said it will not begin a Phase IIb trial this half of AVA-101 to treat wet age-related macular degeneration (AMD), as previously planned. Amusa said the news was consistent with his expectations, and believes the market reaction "may have been due to consensus...

Read the full 513 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >